Featured CDSI Research of Dr. Elizabeth Phillips

Dr. Elizabeth Phillips is an international leader in drug hypersensitivity, studying genetic risk, mechanisms, and outcomes of severe and life-threatening immune-mediated adverse drug reactions. She continues to translate this knowledge into prescribing safer drugs for patients and families.

Elizabeth J. Phillips, MD, FRCPC, FRACP, FIDSA, FAAAAI, is the John A. Oates Chair in Clinical Research; Professor of Medicine, Dermatology; Pharmacology; Pathology, Microbiology and Immunology; and Founder and Director, Center for Drug Safety and Immunology at Vanderbilt University Medical Center.


Dr. Phillips is a world leader in translational approaches to drug hypersensitivity and has pioneered the discovery and implementation of immunogenomic predictors, immunopathogenesis, and novel technologies to improve the safety of drugs into clinical practice.  

Current Focus: 

Dr. Phillips is the Principal Investigator on several NIH-funded research projects to define genetic and other markers that can lead to the prediction, prevention, and earlier diagnosis of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.

Below are the studies in which Dr. Phillips is the principal investigator (PI), followed by studies she co-investigates.